secwatch.observer — SEC 8-K summary
======================================

Issuer:     Roivant Sciences Ltd. (ROIV)
CIK:        0001635088
Form:       8-K
Filed at:   2023-12-20T23:59:59+00:00
Accession:  0001140361-23-058688
Event type: other_material
Sentiment:  positive
Materiality: 0.75
Item codes: 7.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Roivant reports positive Phase 2 batoclimab data in Graves' disease; response >50%
--------------------------------------------------------------------------------

- Initial cohort in Phase 2 trial of batoclimab in Graves' disease showed response rates meaningfully exceeding 50%.
- Batoclimab 680 mg SC achieved up to 87% IgG reduction, mean 81% at 12 weeks; 340 mg showed lower reductions.
- Across clinical parameters, numerically higher responses with 680 mg vs 340 mg, including ATD dose reduction and discontinuation.
- Batoclimab generally well tolerated with no new safety signals observed in the initial data set.
- Immunovant plans to focus future Graves' development on IMVT-1402, with details expected later in 2024.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1635088/000114036123058688/0001140361-23-058688-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1635088/000114036123058688/ef20017126_8k.htm
  HTML page:      https://secwatch.observer/filing/0001140361-23-058688

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer